Martha D. Gay

Georgetown University — United States

Neuroscience · Life Sciences

9h-index325citations39works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuropeptides and Animal Physiology(11), Lung Cancer Research Studies(9), Hepatocellular Carcinoma Treatment and Prognosis(8), Neuroendocrine Tumor Research Advances(8), Liver Disease Diagnosis and Treatment(7)

Publications38 total

Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth
Cell Communication and Signaling·2026Open Access
Abstract 6348: Cholecystokinin receptor blockade modulates in vitro fibrosis gene expression
Cancer Research·2025
1151 ROLE OF A CCK RECEPTOR ANTAGONIST PROGLUMIDE IN MANAGEMENT OF CHRONIC PANCREATITIS - PHASE 1 STUDY
Gastroenterology·2024
The Role of a Cholecystokinin Receptor Antagonist in the Management of Chronic Pancreatitis: A Phase 1 Trial
Pharmaceutics·2024· 7 citedOpen Access
Implicating the cholecystokinin B receptor in liver stem cell oncogenesis
American Journal of Physiology-Gastrointestinal and Liver Physiology·2024· 2 citedOpen Access
Implicating the cholecystokinin B receptor in liver stem cell oncogenesis
Physiology·2023
Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
2023Open Access
Supplementary Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
2023Open Access
Supplementary Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
2023Open Access
Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
2023Open Access
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma
International Journal of Molecular Sciences·2023· 7 citedOpen Access
Treatment with a cholecystokinin receptor antagonist, proglumide, improves efficacy of immune checkpoint antibodies in hepatocellular carcinoma
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
Does Chronic Use of High Dose Proton Pump Inhibitors Increase Risk for Pancreatic Cancer?
Pancreas·2022· 9 citedOpen Access
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
Clinical Pharmacology & Therapeutics·2022· 9 citedOpen Access
Tu1322: PHASE 1 STUDY TO TEST SAFETY AND DOSE OF A CHOLECYSTOKININ RECEPTOR ANTAGONIST, PROGLUMIDE, IN NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Gastroenterology·2022
Tu1306: PROGLUMIDE REVERSES NONALCOHOLIC STEATOHEPATITIS BY INTERACTION WITH THE FARNESOID X RECEPTOR AND ALTERING THE MICROBIOME
Gastroenterology·2022· 1 cited
Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment
Pharmaceutics·2022· 4 citedOpen Access
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
International Journal of Molecular Sciences·2022· 12 citedOpen Access
The CCK-B receptor: A novel target for therapy of hepatocellular carcinoma.
Journal of Clinical Oncology·2022· 1 cited
Educational initiative in an NCATS TL1 training program to address the impact of systemic racism on human health, biomedical research, and the translational scientist
Journal of Clinical and Translational Science·2022· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jill P. Smith(30), Narayan Shivapurkar(27), Hong Cao(20), Robin D. Tucker(19), Anita Safronenka(10), Alexander Kroemer(10), Bhaskar Kallakury(9), Sandeep Nadella(8), Zoe X. Malchiodi(7), Hong Cao(7), Felice H. Liu(5), Victor Ciofoaia(5), Sunil Bansal(5), Amrita K. Cheema(5), Wenqiang Chen(5), Matthew Huber(4), John Kwagyan(4), Aiwu Ruth He(4), Annie J. Kruger(3), Coleman I. Smith(3)